The financing round was led by Maven Capital Partners alongside the government-backed Future Fund.
"Despite an incredibly challenging year, the Hive platform continues to provide a key service to more and more organisations as they evolve their remote working operation. Today’s transaction is a further testament to all that Hive has achieved since we originally invested in 2019 and our belief in the future growth of the company. John and his team have created a strong business and we look forward to working with them as they accelerate their development plans."
EQT Ventures led the Series B round, which will fund team expansion and product development.
"Unmind was built on the belief that everyone has the right to a healthy mind. Thanks to the support from our investors, this round of funding gives us the opportunity to scale our team while further developing the product with clinically-backed insights and research. In turn, this will help us to meet growing global demand from employers looking to drive positive cultural change around mental health in the workplace. At Unmind, we see the future of mental healthcare rooted in prevention. After all, we all have mental health, all of the time, and just like physical health or dental health, there’s a range of ways we can proactively nurture and improve it."
— Nick Taylor, Clinical Psychologist, Co-founder and CEO
The seed follow-on round was led by Adelpha and brings total funding to £1.8m.
"Over the last 20 years the creative industries have undergone seismic change. Part of that change is the growth in freelance – allowing companies and individuals to work faster, smarter and more efficiently. Accessing that talent with speed and effectiveness is vital. GENIE is the answer. Their technology and years of experience deliver best-in-class creative talent. Serving both creative ambition and business growth."
Angel investors backed the employee engagement platform in its debut funding round.
"I have never led a funding round before and I had no idea what I was doing but I thoroughly enjoyed meeting our potential investors and sharing our vision with them. Having read many generic and boring investment press releases before, I thought I would simply share with you why some of the angels invested. Here you go…"
The seed round was backed by private investors establishing QantX Ventures to fund clinical development.
"We are excited to become part of the Neuronostics journey, they have pioneered innovative technology that will make a significant positive difference to the lives of many people around the world."
